Bio-Techne Corp. has announced that its Ella benchtop immunoassay platform has received CE-IVD marking, allowing for clinical use across the European Union. This certification enables hospitals, labs, and developers to utilize Ella for test development and clinical trials. The milestone expands Ella’s application from research to clinical settings, supporting Bio-Techne’s strategy for precision diagnostics and biomarker detection standardization.

Read more at Nasdaq, Inc.: Bio-Techne’s Ella Immunoassay Platform Receives CE-IVD Marking In EU